According to Caprion, the company plans to use Primity's assets to expand its existing immunology and molecular profiling business.
The company is testing a five-protein panel in longitudinal samples to see if it could help with early detection and prediction of progression in Alzheimer's.
Caprion will use its mass spec platform to measure Alzheimer's-linked proteins in the CSF of more than 200 patients and controls over three or more years.
The company expects its purchase of ImmuneHealth's immune monitoring laboratory will help it win business for clinical work requiring fresh sample analysis.
Caprion said it will use the lab to expand its immune monitoring offering and strengthen its business partnerships and research collaborations in Europe.
Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.
GHO, a London-based investment firm, purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012.
The study, which looked at markers of immune senescence in older patients, suggests the platform could be useful in diagnostic and companion diagnostic work.
The company hopes to launch the test sometime this year after completing CLIA certification of its clinical laboratory and securing reimbursement.
The agreement gives Caprion, which did significant development work on the test, exclusive rights to market and commercialize Xpresys Lung inCanada.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.